Hypothesis\n\nAging increases nuclear lamina stiffness, which alters chromatin accessibility and skews caspase‑activated DFFB and extracellular DNASE1L3/L1 activity toward generating long (>500 bp) cfDNA fragments that retain nucleosome‑protected methylation patterns. These long fragments circulate longer because of reduced hepatic clearance and, depending on their CpG methylation status, differentially engage endosomal TLR9: hypomethylated long cfDNA acts as a potent TLR9 agonist, driving NF‑κB‑mediated inflamm‑aging, whereas hypermethylated long cfDNA is tolerogenic. Consequently, the length‑stratified methylation signature of plasma cfDNA predicts inflamm‑aging biomarkers independently of total cfDNA load, and manipulating lamina stiffness or DNASE1L3 activity will shift the long‑fragment methylation pool and alter inflamm‑aging readouts.\n\n## Testable Predictions\n\n1. In human plasma, the ratio of long (>500 bp) to short cfDNA fragments will correlate positively with serum IL‑6 and CRP after adjusting for age, total cfDNA concentration, and comorbidities (predicted r > 0.3, p < 0.01).\n2. Bisulfite‑free methylation profiling of long versus short fragments (using FRAGMA) will reveal that long fragments are significantly hypomethylated at a subset of 50 CpG sites located in TLR9‑activating motifs (e.g., unmethylated CpG dinucleotides within GC‑rich sequences) compared with short fragments.\n3. In vitro, adding recombinant DNASE1L3 to plasma from older donors will decrease the long‑fragment proportion and increase methylation at the same CpG sites, concomitant with reduced TLR9‑dependent NF‑κB activation in human monocyte cultures.\n4. In aged mice, genetic reduction of lamin A/C (Lmna^+/-) will lower nuclear stiffness, increase the long‑cfDNA fraction, and exacerbate inflamm‑aging markers; conversely, overexpression of lamin A/C will reduce long cfDNA and attenuate inflamm‑aging.\n\n## Falsifiability\n\nIf long cfDNA fraction does not predict inflamm‑aging markers after controlling for total cfDNA and age, or if long fragments show no methylation bias at TLR9 motifs, the hypothesis is refuted. Likewise, if DNASE1L3 treatment fails to alter long‑fragment abundance or monocyte NF‑κB response, the proposed nuclease‑mediated mechanism is unsupported.\n\n## Experimental Outline\n\n- Collect plasma from 200 participants spanning 20‑90 years; measure total cfDNA, fragment size distribution via low‑pass sequencing, and inflamm‑aging cytokines.\n- Separate long and short cfDNA using size‑selective SPRI beads; apply FRAGMA to quantify methylation at preselected CpG motifs.\n- Perform TLR9‑dependent NF‑κB luciferase assay in THP‑1 cells treated with isolated long or short cfDNA ± TLR9 antagonist.\n- Treat aliquots of aged plasma with recombinant DNASE1L3 or lamin A/C‑siRNA‑treated hepatocyte conditioned media to assess clearance effects.\n- Validate findings in Lmna^+/- and Lmna^over mice; assess plasma cfDNA length, methylation, and serum inflamm‑aging markers.\n\n## Implications\n\nConfirming that long cfDNA fragments act as methylation‑sensitive immunomodulators would mechanistically link nuclear architecture defects to inflamm‑aging, offering a new intervention point (e.g., DNASE1L3 augmentation or lamina‑targeted therapies) to modulate epigenetic biomarkers of aging.
